Telia finds healthy future for disease monitoring unit
Telia has sold its health monitoring portfolio to Addlife, a Swedish medical technology company.
Telia Health Monitoring will join Swedish IT and robotics company Camanio, which Addlife bought three weeks ago. The companies did not give a price for the transaction, which is likely to be completed in early 2022.
Brendan Ives, head of Telia’s so-called Division X, which builds new businesses and markets, said: “We are pleased to have found a new home for Telia Health Monitoring on AddLife, which is a life science company and which shares our vision of improving people’s lives.”
Kristina Willgård (pictured), CEO of AddLife, said: “Digital care and better data support can both improve the quality of life for patients while delivering more efficient care. The combination of the offer from Camanio with the solution from Telia Health Monitoring gives us great opportunities to actively support care providers in the development of the digital care and care of the future.”
Ives added: “They understand the value of the strong position we have developed and taken over a number of years in remote monitoring of health. With their broad portfolio, entrepreneurial spirit and European presence, we believe that they are uniquely positioned to take this business to the next level.”
Telia said that the business has agreements with eight regions in both the public and private sectors in Sweden. In total, about 1,000 patients are connected to the solution, which is scalable and can handle a growing number of patients and their unique needs.
Telia said its digital health monitoring solution supports self-monitoring of a number of chronic diseases, such as heart failure, high blood pressure, chronic obstructive pulmonary disease (COPD), diabetes and inflammatory bowel disease (IBD).
But it has also been developed for self-monitoring in specialist maternity care.
Willgård added: “Our vision is to improve people’s lives and we see a major societal challenge in healthcare with a growing and aging population with chronic diseases.”